Basic Sustainability Policy and Setting of Material Issues
First written in FY2024. 1 of 2 entries say "Restated". Latest entry: FY2025.
The whole theme swung hardest in 2019: 1 of 9 companies on the "Worse" side.
37 other companies' latest entry also says "Restated".
- FY2025RestatedAnnual report
「Under our corporate philosophy, "Contributing to global healthcare through cutting-edge antibody technology," we aim to develop new antibody therapeutics by leveraging our proprietary antibody technologies. Our basic sustainability policy is to develop useful and safe antibody therapeutics by actively advancing our core drug discovery business, thereby enhancing corporate value through sustainable growth and contributing to the realization of a sustainable society through our business activities.」
The company has reconfirmed its basic sustainability policy of developing useful and safe antibody therapeutics through its drug discovery business, enhancing corporate value, and realizing a sustainable society. - FY2024First statedAnnual report
「Under our corporate philosophy, "Contributing to global healthcare through cutting-edge antibody technology," we aim to develop new antibody therapeutics by leveraging our proprietary antibody technologies. Our basic sustainability policy is to develop useful and safe antibody therapeutics by actively advancing our core drug discovery business, thereby enhancing corporate value through sustainable growth and contributing to the realization of a sustainable society through our business activities.」
The company has systematically presented for the first time its basic sustainability policy of developing useful and safe antibody therapeutics through its drug discovery business, enhancing corporate value, and realizing a sustainable society, and has established its material issues.